Akari Therapeutics Shares Jump 50% on KRAS Data

Akari Therapeutics shares surged ~50% in after‑hours trading on 22 May 2026 after releasing preclinical KRAS‑combination data.
The study showed AKTX‑101 ADC with KRAS inhibitor adagrasib produced synergistic cell killing in pancreatic cancer lines harboring G12D and G12C mutations.
AKTX‑101 uses Akari’s PH1 RNA spliceosome‑modulating payload, enabling degradation of KRAS‑mutant pre‑mRNA and differentiating it from topoisomerase‑I TROP2 ADCs.
The company has started IND‑enabling work for AKTX‑101 and aims to begin a Phase 1 first‑in‑human trial by mid‑2027.